Cor Vasa 2015, 57(3):377-380

Účinnost a bezpečnost inhibitoru proprotein konvertázy subtilisin/kexin typu 9 alirocumabu u nemocných s vysokým kardiovaskulárním rizikem: studie ODYSSEY COMBO I

Michal Vrablík
Centrum preventivní kardiologie, III. interní klinika - klinika endokrinologie a metabolismu, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha

Published: June 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Účinnost a bezpečnost inhibitoru proprotein konvertázy subtilisin/kexin typu 9 alirocumabu u nemocných s vysokým kardiovaskulárním rizikem: studie ODYSSEY COMBO I. Cor Vasa. 2015;57(3):377-380.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. M. Abifadel, M. Varret, J.P. Rabes, et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nature Genetics 34 (2003) 154e6. Go to original source... Go to PubMed...
    2. R.T. Dadu, C.M. Ballantyne, Lipid lowering with PCSK9 inhibitors, Nature Reviews. Cardiology 11 (2014) 563-575. Go to original source... Go to PubMed...
    3. M. Abifadel, S. Elbitar, P. El Khoury, et al., Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs, Current Atherosclerosis Reports 16 (2014) 439-462. Go to original source... Go to PubMed...
    4. D.J. Kereiakes, J.G. Robinson, C.P. Cannon, et al., Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study, American Heart Journal 169 (2015) 906-915.e13. Go to original source... Go to PubMed...
    5. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, et al., Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, American Journal of Human Genetics 79 (2006) 514e23. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes